Enveric Biosciences (ENVB) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Enveric Biosciences Inc: On Nov 20, Nasdaq Issued Delisting Notice on Failing to Meet Minimum Bid Price Requirement
ReutersNov 22 16:47 ET
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
BenzingaNov 19 06:30 ET
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
BenzingaNov 18 10:06 ET
Enveric Biosciences 3Q Loss/Shr 24c >ENVB
Dow JonesNov 14 16:23 ET
Enveric Biosciences | 10-Q: Q3 2024 Earnings Report
SECNov 14 16:17 ET · Announcements
Enveric Biosciences | 8-K: Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
SECNov 14 16:14 ET

Comments

dSuu

Nov 21 07:50

$Enveric Biosciences (ENVB.US)$ whoaaaaaa

1

4

Jaguar8

Nov 12 08:09

NEWS

$Enveric Biosciences (ENVB.US)$
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Enveric Biosciences (NASDAQ: ENVB)has signed a licensing agreement with MycoMedica Life Sciences for its EVM201 program, including drug candidate EB-002, a synthetic prodrug for treating neuropsychiatric disorders. The agreement includes potential milestone payments up to $62 million plus tiered single-digit royalties on future sales. MycoMedica receives exclusive globa...

Trytosaveabit

Nov 12 08:06

News

$Enveric Biosciences (ENVB.US)$ Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Benzinga· 4 mins ago

Jaguar8

Oct 22 03:19

Put alerts on this

$Enveric Biosciences (ENVB.US)$

7

4

Sean Parker

Oct 19 13:40

next DRUG hopefully. watch it

$Enveric Biosciences (ENVB.US)$
Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug, which, if approved, could have been the first psychedelic-assisted therapy.
Midomafetamine, based on the mind-altering drug MDMA, commonly known as Ecstasy or Molly, was rejected by the FDA in August for the treatment of post-traumatic stress disorder...

1

10

Sean Parker OP : In addition to Bright Minds Bio (NASDAQ:DRUG), other notable gainers included 180 Life Sciences ( $180 Life Sciences (ATNF.US)$ ), Clearmind Medicine ( $Clearmind Medicine (CMND.US)$ ), Mind Medicine ( $Mind Medicine (MNMD.US)$ ), GH Research ( $GH Research (GHRS.US)$ ), Cybin ( $Cybin (CYBN.US)$ ), Atai Life Sciences ( $ATAI Life Sciences (ATAI.US)$ ), Revive Therapeutics (OTCQB:RVVTF), Enveric Bio ( $Enveric Biosciences (ENVB.US)$ ), and COMPASS Pathways ( $COMPASS Pathways (CMPS.US)$ ).

Report
Reply

Cancel Reply
Arrayfunction : Yikes. The comment about independent review is unsettling. That's not something that should be happening. The entire trial design, including how the results will be analyzed and reported would have had to been approved before the start unless they intentionally YOLO'd

Report
Reply

Cancel Reply
Sean Parker OP Arrayfunction : that's how drug was in the beginning. I had quite a few shares waiting on them to approve what they had. i waited for a couple months and gave up on the idea. I sold 2 months ago and missed out on all the recent gains. I'm not saying to buy anything at all, I haven't even bought into any of these yet. I just put them all on there own watch list and hope for good news. also, I just like posting things for people like you to give your opinion.

Report
Reply

Cancel Reply
Arrayfunction Sean Parker OP : Sorry for the confusion! I was actually doing exactly what you had intended. I may not have been clear It was just a comment as I don't know if I have ever seen that before. I didn't take your post as any sort of advice so there was nothing I could be criticizing. My bad!

Report
Reply

Cancel Reply
Sean Parker OP Arrayfunction : no worries at all. I didn't take it that way. I appreciate everyone's input.

Report
Reply

Cancel Reply

View more comments...

ENVB Enveric Biosciences

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target